Cargando…

RESOLVE-ing sepsis in children – not yet!

The Researching Severe Sepsis and Organ Dysfunction in Children: A Global Perspective study of drotrecogin alfa activated versus placebo was the largest study of adjunctive therapy ever performed in children with severe sepsis. Despite this, the study failed to show any significant differences in ou...

Descripción completa

Detalles Bibliográficos
Autor principal: Nadel, Simon
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2007
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2206411/
https://www.ncbi.nlm.nih.gov/pubmed/17561989
http://dx.doi.org/10.1186/cc5919
_version_ 1782148465563795456
author Nadel, Simon
author_facet Nadel, Simon
author_sort Nadel, Simon
collection PubMed
description The Researching Severe Sepsis and Organ Dysfunction in Children: A Global Perspective study of drotrecogin alfa activated versus placebo was the largest study of adjunctive therapy ever performed in children with severe sepsis. Despite this, the study failed to show any significant differences in outcome between the treatment and placebo groups. The results raise questions about how we should perform meaningful clinical trials in relatively rare conditions such as paediatric sepsis, where the easily measurable endpoints (such as death) are infrequent. A radical rethink of the design of such studies is urgently needed.
format Text
id pubmed-2206411
institution National Center for Biotechnology Information
language English
publishDate 2007
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-22064112008-01-19 RESOLVE-ing sepsis in children – not yet! Nadel, Simon Crit Care Commentary The Researching Severe Sepsis and Organ Dysfunction in Children: A Global Perspective study of drotrecogin alfa activated versus placebo was the largest study of adjunctive therapy ever performed in children with severe sepsis. Despite this, the study failed to show any significant differences in outcome between the treatment and placebo groups. The results raise questions about how we should perform meaningful clinical trials in relatively rare conditions such as paediatric sepsis, where the easily measurable endpoints (such as death) are infrequent. A radical rethink of the design of such studies is urgently needed. BioMed Central 2007 2007-06-08 /pmc/articles/PMC2206411/ /pubmed/17561989 http://dx.doi.org/10.1186/cc5919 Text en Copyright © 2007 BioMed Central Ltd
spellingShingle Commentary
Nadel, Simon
RESOLVE-ing sepsis in children – not yet!
title RESOLVE-ing sepsis in children – not yet!
title_full RESOLVE-ing sepsis in children – not yet!
title_fullStr RESOLVE-ing sepsis in children – not yet!
title_full_unstemmed RESOLVE-ing sepsis in children – not yet!
title_short RESOLVE-ing sepsis in children – not yet!
title_sort resolve-ing sepsis in children – not yet!
topic Commentary
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2206411/
https://www.ncbi.nlm.nih.gov/pubmed/17561989
http://dx.doi.org/10.1186/cc5919
work_keys_str_mv AT nadelsimon resolveingsepsisinchildrennotyet